Wittycell, set up in 2005 as a spin-off from the French Institute Jean Godinot, is a biotechnology company developing novel therapeutic and prophylactic vaccine adjuvants in the field of oncology and infectious diseases.
Company (Alive / Active)
|Investor||Investor Type||Location||Participating Rounds|
|Title||Application Date||Patent Date||Status
(Patent / Application)
|Increase of immune response and targeting by antigens and/or drug linkage||Nov 07, 2008||Feb 04, 2014||Patent|
|Compositions for and methods of enhancing the immune response to antigens||Dec 05, 2008||Jul 03, 2012||Patent|
|Compositions for and methods of enhancing the immune response to antigens||Dec 05, 2008||Jun 26, 2012||Patent|